Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728596 · ClinicalTrials.gov registry record · NA
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A NA study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 3,665
- Enrollment target
NCT02728596 is a NA study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 3,665 participants.
The verdict
NCT02728596, a NA study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,665 participants
- Enrollment target
Study Summary
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Preventive Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,665 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2021-08-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02728596
The ClinicalTrials.gov registry entry for NCT02728596 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02728596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02728596 about?
NCT02728596 is a clinical study titled "S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)". This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile ...
What is the current status of trial NCT02728596?
This trial is currently completed. It is a NA study. The enrollment target is 3,665 participants. The study started on 2016-10-07. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT02728596?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Preventive Intervention (OTHER).
Who is sponsoring clinical trial NCT02728596?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.